NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

  • STATUS
    Recruiting
  • End date
    Dec 1, 2025
  • participants needed
    56
  • sponsor
    National Cancer Institute (NCI)
Updated on 12 September 2021
cancer
monoclonal antibodies
systemic therapy
measurable disease
protease
direct bilirubin
atazanavir
doxorubicin
cytotoxic chemotherapy
progressive disease
neutrophil count
AIDS
cancer chemotherapy
systemic chemotherapy
lung exam

Summary

Background

Kaposi sarcoma (KS) tumors grow on the skin, lymph nodes, lungs, bone, and gastrointestinal tract. KS often affects people with immune deficiencies, such as among people living with HIV or those with prior history of transplant. Researchers want to see if 2 non-chemotherapy drugs can help people with KS. NHS-IL12 triggers the immune system to fight tumors. M7824 blocks the pathways that cancer cells use to stop the immune system from fighting tumors.

Objective

To learn if giving NHS-IL12 alone or with M7824 could help the immune system fight KS tumors.

Eligibility

People 18 and older with KS that has been treated with chemotherapy or immunotherapy

Design

Participants will be screened with some or all of the following:

medical history

physical exam

chest X-ray

computed tomography scan

blood and urine tests

electrocardiogram and echocardiogram

skin KS lesion biopsy

lung exam

gastrointestinal exam

All participants will get NHS-IL12 every 4 weeks for up to 96 weeks (or 24cycles). It is injected under the skin.

Some participants will also get M7824 every 2 weeks for up to 96 weeks (or 24cycles). It is given through a plastic tube that is put in an arm vein.

Participants will complete questionnaires about how KS affects their quality of life. Their KS lesions will be measured and photographed. They will repeat some of the screening tests. They will give saliva samples or additional tissue samples. They will have a lung function test. Their ability to perform their normal activities will be assessed. The treatment duration is up to 96 weeks (or 24cycles) with an option to take NHS-IL12 and/or M7824 until the KS tumors are not responding, or you develop unacceptable side effects.

Participants will have follow-up visits 7 and 30 days after treatment ends, then every 3 to 6 months for the next 18 months, then once a year for 3 years.

Description

Background
  • Kaposi Sarcoma (KS) is a multicentric angioproliferative tumor, caused by Kaposi sarcoma-associated herpesvirus, that most frequently involves the skin, but may also involve lymph nodes, lungs, bone and gastrointestinal tract. It is most common in people with HIV but may also occur in patients without a diagnosis of HIV. Patients with HIVassociated KS have worse survival than HIV-infected patients without KS.
  • As it is a relapsing and remitting condition, patients with KS often require prolonged courses of cytotoxic chemotherapy.
  • KS is an immune responsive tumor as interferon-alpha, pomalidomide, and restoring Tcell function in HIV + patients treated with antiretroviral drugs can result in clinical benefit and remission of KS.
  • Published Phase I/II studies by our group demonstrated that IL-12 alone and in combination with liposomal doxorubicin led to clinical responses in patients with advanced KS.
  • NHS-IL12 (M9241) is an immunocytokine with affinity to both single and double stranded DNA allowing for targeting of exposed DNA, which is commonly seen in necrotic tumors. This agent is able to deliver IL-12 to the tumor microenvironment promoting local immunomodulation, that results in less systemic toxicity than IL-12 systemic administration.
  • M7824 is a novel bifunctional fusion protein composed of a monoclonal antibody against human PD-L1 (avelumab) fused with the extracellular domain of human TGF-beta receptor II (TGF- RII), which functions as a TGF-beta trap .
  • Anti-PD-L1 and anti-PD-1 agents have been found to be active in certain virus-induced cancers, including Kaposi sarcoma, and to be safe and active in patients with HIV infection.
  • Currently, no clinical data exists for the combination of NHS-IL12 and M7824. Preclinical data suggest synergy between these agents from existing ongoing studies and the available clinical data both in KS and other tumor subtypes suggest that the combination of NHSIL12 with M7824 is likely to be well-tolerated and has scientific rationale. This combination offers a new treatment approach for patients with advanced KS who have received prior therapies.
    Objectives

-Evaluate the safety and tolerability of single agent NHS-IL12 and the combination of NHSIL12 with M7824 in patients with advanced KS.

Eligibility
  • Age >18 years
  • Histologically confirmed Kaposi sarcoma (KS)
  • KS requiring systemic therapy, with a history of prior systemic therapy:
  • 2 weeks from last chemotherapy
  • 4 weeks from last immunotherapy
  • At least five measurable cutaneous KS lesions with no previous local radiation, surgical or intralesional cytotoxic therapy to these measurable lesions.
  • ECOG Performance Status (PS) less than or equal to 2
  • Patient must be willing to give informed consent.
  • Patients can be HIV positive or negative.
  • Antiretroviral therapy (ART) for HIV+ patients for 8 or more weeks prior to entry with an HIV viral load of <400 copies/ml and CD4+ T-cell count >50 cells/microliter.
  • Patients with bleeding from visceral sites of KS or requiring blood transfusions in the 2 weeks prior to study entry will not be eligible.
Design
  • This is a Phase I/II study assessing the safety and efficacy of NHS-IL12 alone or in combination with M7824 in patients with advanced KS. Patients will receive therapy until optimal tumor response, unacceptable toxicity, the patient s request to discontinue therapy, PI decision, up to a total of 96 weeks, or 24 cycles.
  • Monotherapy: Patients will receive NHS-IL12 alone with a 3+3 design applicable to the first 3-6 patients at a starting dose of 16.8 microgram/kg on day 1 of a 28-day cycle. Two dose de-escalation levels (Dose Level -1: 12 microgram/kg or Dose Level -2: 8 microgram/kg) will be permitted if there is evidence of 2 or more dose limiting toxicities within the first 6 weeks of therapy.
  • Combination Therapy: The combination arm will open following accrual and completion of the the DLT period for patients in the monotherapy arm. Up to 28 patients will be treated with M7824 (1200 mg IV, every 2 weeks) and NHS-IL12 (MTD dose from the monotherapy arm). The DLT period for this arm will be 6 weeks.

Details
Condition Kaposi's Sarcoma, Sarcoma, Sarcoma (Pediatric), Soft Tissue Sarcoma, kaposi sarcoma
Treatment NHS-IL12, M7824, M7824+M7824, NHS-IL12+M7824
Clinical Study IdentifierNCT04303117
SponsorNational Cancer Institute (NCI)
Last Modified on12 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients with biopsy proven (confirmed in the Laboratory of Pathology, CCR) Kaposi sarcoma (KS)
KS requiring systemic therapy, with a history of prior therapy
T1 KS or T0 KS sufficiently widespread that systemic therapy is advisable, or KS affecting quality-of-life due to local symptoms or psychological distress OR
KS patients with an inadequate response to liposomal doxorubicin, paclitaxel, other systemic chemotherapy (either progressive disease or stable disease after 3 or more cycles) or immunotherapy (progressive disease)
A wash-out period off treatment of 2 weeks from last chemotherapy and 4 weeks from last immunotherapy, other systemic treatment with a biologic agent, or monoclonal antibody therapy will be required
Resolution of toxicity from prior therapy to less than or equal to Grade 1
At least five measurable cutaneous KS lesions with no previous local radiation, surgical or intralesional cytotoxic therapy that would prevent response assessment for that lesion
Measurable disease by the criteria proposed by the AIDS Clinical Trials Group (ACTG) Oncology Committee for KS
Patients can be HIV positive or negative
ART for HIV+ patients for 8 or more weeks prior to entry with an HIV viral load of <400 copies/ml at screening and CD4+ T cell count of >50 cells/ (NotEqual)L as this may be expected if patients have received several courses of chemotherapy
Age greater than or equal to18 years
ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to 60%)
Patients must have adequate organ and marrow function as defined below
absolute neutrophil count greater than or equal to 1,500/mcL
platelets greater than or equal to 100,000/mcL
total bilirubin within normal institutional limits; OR <3x institutional ULN for Gilbert s syndrome or HIV protease inhibitors; OR <5x ULN and direct bilirubin < 0.7mg/dL for patients on atazanavir-containing HIV regimen
AST(SGOT)/ALT(SGPT) less than or equal to 1.5 X institutional upper limit of normal
hemoglobin greater than or equal to 9g/dL
Creatinine within normal institutional limits OR creatinine clearance >30 mL/min/1.73m^2 as estimated by either Cockroft-Gault of 24- hour urine collection for patients with creatinine levels above institutional normal
The effects of NHS-IL12 and M7824 on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during treatment and for at least 4 months after the last dose of treatment and agree to inform the treating physician immediately if they become pregnant. Also, there is unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with M7824 and/or NHS-IL12, therefore female patients must agree to discontinue breastfeeding if treated with these agents
Normal international normaoized ration (INR), PT less than or equal to 1.5 x ULN and activated partial thromboplastin time (aPTT) less than or equal to 1.5 x ULN
Ability of subject to understand and the willingness to sign a written informed consent document

Exclusion Criteria

Patients who are receiving any other investigational agents
Pregnant women are excluded from this study as the effects of NHS-IL12 and M7824 have potential teratogenic or abortifacient effects
Severe KS (such as symptomatic pulmonary KS) that could be life threatening if it progressed over 2-4 weeks
Actively bleeding sites caused by visceral KS
Patients who are actively bleeding and/or requiring transfusions in the 2 weeks preceding study entry
Subjects unwilling to accept blood products as medically indicated
Patients with history of bleeding, diathesis, or recent major bleeding events within a period of 4 weeks considered by the investigator as high risk for investigational drug treatment
Active multicentric Castleman disease
Patients with any active or recent history (symptomatic in the last 3 months) of a known or suspected autoimmune disease (with the exception of diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment) or recent history of a syndrome that required systemic corticosteroids (10mg daily prednisone or equivalent) or immunosuppressive medications except inhaled steroids and adrenal replacement steroids doses up to 10mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.Uncontrolled opportunistic infections
Patients with primary effusion lymphoma
History of malignant tumors other than KS, unless
In complete remission for greater than or equal to 3 years from the time complete remission was first documented or
Resected basal cell or squamous cell carcinoma of the skin or
In situ cervical or anal dysplasia
History of allergic reactions attributed to compounds of similar chemical or biologic composition to NHS-IL12 and/or M7824 investigational agents used in study
Active tuberculosis (TB)
Patients who are undergoing first month of therapy (RIPE or equivalent) for active TB or
Patients with TB immune reconstitution syndrome (IRIS) requiring corticosteroids
Uncontrolled substantial intercurrent illness including, but not limited to, ongoing or active severe infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, that would limit compliance with study requirements
Medical or psychiatric illness or social situation that would, in the opinion of the investigator, preclude participation in the study or the ability of patients to provide informed consent for themselves
Patients who have received or will receive a live vaccine within 30 days prior to the first administration of study intervention. Seasonal flu vaccines that do not contain a live virus are permitted. Locally approved COVID vaccines are permitted
Uncontrolled HBV infection, defined as plasma HBV DNA detectable by PCR
Note: the following will NOT be exclusionary
A positive hepatitis B serology indicative of previous immunization (i.e. HBsAb positive and HBcAb negative), or a fully resolved acute HBV infection
Patients with chronic HBV suppressed by appropriate antiretroviral therapy with activity against HBV, as outlined in DHHS guidelines
Uncontrolled HCV infection, defined as plasma HCV DNA detectable by PCR
Note: the following will NOT be exclusionary
Positive HCV serology but no detectable HCV RNA, indicative of spontaneously cleared HCV infection
Patients who have been successfully treated for HCV as long as therapy for HCV has been completed
Patients will be excluded from the combination therapy arm if
they have discontinued prior PD1/L1 blocking agent due to immune mediated adverse event(s) OR
they have active non-infectious pneumonitis or a history of steroid requiring non-infectious pneumonitis
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note